Comparative Renoprotective Effect of Febuxostat and Allopurinol in Predialysis Stage 5 Chronic Kidney Disease Patients: A Nationwide Database Analysis
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.1697
Abstract: Hyperuricemia has been associated with chronic kidney disease (CKD) progression. The antihyperuricemic febuxostat's potential renoprotective effect has been demonstrated in stage 1–3 CKD. Large‐scale studies comparing the renoprotective potential of febuxostat and allopurinol in advanced… read more here.
Keywords: predialysis stage; febuxostat; stage; febuxostat allopurinol ... See more keywords
Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial
Sign Up to like & getrecommendations! Published in 2022 at "RMD Open"
DOI: 10.1136/rmdopen-2021-001944
Abstract: Objectives The Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial suggested a higher risk of cardiovascular (CV) death from febuxostat than from allopurinol. However, a significant number of patients died after… read more here.
Keywords: febuxostat allopurinol; cares trial; death; discontinuation febuxostat ... See more keywords
Comparing the Effects of Febuxostat and Allopurinol in an Animal Model of Metabolic Syndrome
Sign Up to like & getrecommendations! Published in 2021 at "Pharmacology"
DOI: 10.1159/000516495
Abstract: Introduction: Recent studies highlighted the association of hyperuricemia and metabolic syndrome (MS). The aim of this study was to compare the beneficial effects of febuxostat versus allopurinol on the biochemical changes that occur in MS.… read more here.
Keywords: comparing effects; allopurinol animal; febuxostat allopurinol; study ... See more keywords